Drug intelligence / Profile preview

ENTSTAR001

Development stage: Preclinical
Lead developer: Entos Pharmaceuticals
Modality: Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Intravitreal, Subretinal, Ophthalmic

Overview

ENTSTAR001 is a gene therapy candidate being developed by Entos for the treatment of Stargardt disease. The therapy utilizes the Fusogenix PLV platform, which is designed to deliver genetic material into target cells. Stargardt disease is an inherited retinal disorder that leads to progressive vision loss, and ENTSTAR001 aims to address this condition through targeted gene delivery.

Targets

ABCA4

Beyond the preview

Go deeper on ENTSTAR001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENTSTAR001.

Explore the full profile